Meet us at the ISN-WCN 23 "World Congress of Nephrology" in Bangkok, 30 March – 2 April 2023!

Logo TauroLock


If you are looking for a catheter lock solution with both an antimicrobial and anticoagulant effect, we recommend TauroLock™. On this site, you can find detailed information about the product, its active ingredients, and application.


Indication and effect

TauroLock™ has been approved for instillation into all CVCs. As a bactericidal and fungicidal lock solution, it prevents the formation of a biofilm. Patients thus remain protected from catheter-related infections and occlusion.
We recommend TauroLock™ for all vascular access devides (VADs) in parenteral nutrition, oncology, and – as an alternative to TauroLock™-HEP500 and TauroLock™-U25.000 – in dialysis.


The two active ingredients of TauroLock™ are taurolidine and 4 % citrate. Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE) against gram-positive and gram-negative bacteria and fungi (e.g. Candida). Citrate works as an anticoagulant, which means it helps to maintain an adequate flow rate within the catheter.


In-between treatment sessions (e.g. dialysis, chemotherapy, parental nutrition), TauroLock™ is instilled into the saline-flushed access system. Please note that medical staff must check the filling volume of the respective catheter or port system.

Expert recommendations


Taurolidine-based lock solutions such as TauroLock™ are recommended in national and international guidelines. Generally speaking, this product may be used for central-venous catheters (CVC) in three different contexts:



Please note that patients must always consult with their attending physician before applying TauroLock™.



There are some cases in which patients should not use TauroLock™:


  • The patient has displayed allergic reactions to either citrate or taurolidine.
  • The patient is currently taking medication which has proven incompatible with either citrate or taurolidine.


Before using the device, you need to aspirate TauroLock™ with a syringe and then flush the VAD with saline. If aspiration is not possible, you may also flush out the solution with saline. Should TauroLock™ inadvertently enter the blood stream, it will quickly degrade into the amino acid taurine. Slow flushing is therefore clinically tolerable. Do not flush lock solutions in infants and children less than two years of age. 

Package sizes

If you would like to purchase TauroLock™, there are two options available:


  • single dose: ampoules of 3 ml or 5 ml (10 ampoules per box)
  • multiple dose: vials of 10 ml (100 vials per box)

Storage & transport

TauroLock™ must be stored at temperatures of 15 °C to 30 °C. Please note that you must not freeze TauroLock™ under any circumstances.

More information about TauroLock


For international guideline recommendations, e.g. ESPEN 2020:

“Recommendation 34: As an additional strategy to prevent CRBSIs, taurolidine locking should be used because of its favorable safety and cost profile. Grade of Recommendation B - Strong consensus (100% agreement).”

Download ESPEN recommendations for TauroLock™ in parenteral nutrition

Recommendation 34: As an additional strategy to prevent CRBSIs, taurolidine locking should be used because of its favorable safety and cost profile. Grade of Recommendation B - Strong consensus (100% agreement)

Download AIEOP recommendations for TauroLock™ in oncology

Recommendations for locking the CVAD:


  1. The use of normal saline is recommended for locking CVADs. (A I)
    Randomized controlled trials have shown no difference between saline and heparinized solution. Saline is preferable due to the greater handling and the lower risk of side effects compared to heparin, especially in the newborn.
  2. Locking with non-antibiotic antibacterial substances (in particular, 2% taurolidine) has been proven effective in pediatric patients in reducing the risk of infection.
    Data on the pediatric cancer population are still limited. (BI)
  3. The use of thrombolytic substances (urokinase 5000 IU/ml or the tissue activator of plasminogen – rtPA 1 mg/ml) is recommended only in case of occlusion of the catheter lumen due to clots. (A II)

Download DGfN recommendations for TauroLock™ in dialysis

Between dialysis treatments, the central venous access device may be locked using a diluted heparin solution. Heparin, however, does not have any antibacterial properties. Antibacterial lock solutions should be preferred since they reduce the rate of catheter-related bacteraemias considerably. The use of antibiotics cannot be recommended due to the potential development of resistance. Alternatively, citrate in various concentrations (4 %, 30 % or 46 %) as well as taurolidine-citrate solutions may be considered. Due to the risk of severe cardiac arrhythmias, highly concentrated citrate must be strictly administered by trained staff according to the instructions of the manufacturer. Citrate at 4 % has proven effective against low potential of complications and is broadly accepted standard amongst citrate lock solutions at present.

For personal inquiries, you can also contact us via phone or email.

Our international distributors based in more than 50 countries are happy to offer support ASAP.